Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

Patient selection and access

The Symplicity™ procedure — which uses the Symplicity Spyral™ renal denervation system — provides another treatment option for patients struggling with hypertension. Read on to understand which patients might benefit from this procedure, how to explain it to them, and how to help them access care. Also be sure to sign up for email updates.

Contact us
Alert Indications, Safety, and Warnings
Decorative element.
Have
uncontrolled hypertension

Consider patients where lifestyle modifications and antihypertensive medications haven’t adequately controlled blood pressure.

Decorative element.
Are willing to undergo an interventional procedure

Consider patients who opt for the Symplicity™ procedure following shared decision-making and an attempt at lifestyle modifications and medical therapy.

30% of patients

would be willing to consider an interventional approach to manage hypertension versus an additional medication.1,2
(N = 400)

Download the ESC guidelines summary

Helping your patients access care

If you think you‘ve identified a potential patient for the Symplicity™ procedure, first review the benefits and risks with them. Use the following resources to support discussions with your patients and help them understand the procedure:

Easily identify patient for the Simplicity™ procedure.

pdf Patient selection guide (.pdf)

2.7MB

Patient selection guide

Learn from the experts on YouTube

Visit our YouTube channel for symposium replays, expert insights, and practical discussions from leading European specialists.

Visit now

Related pages

Sign up for email to stay connected.

We want to provide you with resources that will be the most useful as you acquaint yourself with this procedure.

Sign up so we can send relevant information and resources directly to your inbox.

  

Contact us

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

Contact us

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

a) Statement “Registered under Act 737”
b) Medical device registration number: GC3639922-85853

1

Kandzari DE, Weber MA, Poulos C, et al. Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2023;16(1):e008997. doi: 10.1161/CIRCOUTCOMES.122.008997.

2

Symplicity Spyral™ renal denervation system. Sponsor presentation. U.S. FDA Circulatory Systems Devices Panel. Meeting date August 23, 2023.

3

Kandzari D, Townsend R, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medication. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.

4

FDA Executive Summary Prepared for the August 23, 2023 Meeting of the Circulatory System Devices Panel. Accessed May 20, 2024.